NextCure, Inc.

Company Overview

Business Model: NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative antibody-drug conjugates (ADCs) and other targeted therapies for cancer patients who do not respond to, or have disease progression on, current treatments. The company leverages its core strengths in understanding biological pathways, biomarkers, and the interactions within the tumor microenvironment to identify and advance product candidates. NextCure, Inc. has not yet generated revenue from product sales and anticipates that future revenue generation will depend on the successful clinical development, regulatory approval, and commercialization of its product candidates.

Market Position: NextCure, Inc. is strategically positioned in the ADC field with two clinical-stage candidates: SIM0505, targeting cadherin-6 (CDH6), and LNCB74, targeting B7-H4. The company aims to differentiate its ADCs through unique binding epitopes, proprietary payloads (Topoisomerase 1 inhibitor for SIM0505, Monomethyl auristatin E for LNCB74), and optimized safety and efficacy profiles. The oncology market is highly competitive, with numerous larger pharmaceutical and biotechnology companies, as well as smaller, earlier-stage firms, developing similar therapies. Key competitors for SIM0505 include raludotatug deruxtecan (co-developed by Merck & Co. and Daiichi Sankyo), OnCusp Therapeutics' CUSP06, and Hansoh Pharma’s HS-20124. For LNCB74, competitors include AstraZeneca plc, BeiGene Ltd. (licensed from DualityBio), GSK plc (licensed from Hansoh Pharmaceutical Group Limited), and Day One Biopharmaceuticals, Inc. (acquired Mersana Therapeutics).

Recent Strategic Developments:

• Pipeline Prioritization and Restructuring: In March 2024, NextCure, Inc. implemented a restructuring to prioritize the development of SIM0505 and LNCB74. This initiative included pausing internal manufacturing operations and reducing the workforce by approximately 37%.
• SIM0505 Licensing Agreement: In June 2025, NextCure, Inc. entered into a License Agreement with Simcere Zaiming Pharmaceutical Co., Ltd., securing exclusive worldwide rights (excluding China, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize SIM0505. This agreement involved an upfront cash payment of $12 million, an additional $5 million payment due by December 31, 2025, and a $1.5 million milestone payment upon initiation of the Phase 1 clinical trial in October 2025.
• LNCB74 Co-Development: LNCB74 is being advanced under a 50:50 cost and profit-sharing Research Collaboration and Co-Development Agreement with LigaChem Biosciences, Inc., effective April 1, 2023.
• Financing Activities: In November 2025, NextCure, Inc. completed a private placement, raising $20.3 million (net) through the sale of common stock and pre-funded warrants. Subsequent to year-end, through February 27, 2026, an additional $0.7 million (net) was raised through an at-the-market offering with H.C. Wainwright & Co., LLC.

Geographic Footprint: NextCure, Inc. conducts its operations exclusively in the United States, with its corporate headquarters, laboratory, and warehouse facilities located in Beltsville, Maryland. The company's product candidates, SIM0505 and LNCB74, are being developed for global markets, with SIM0505 licensed for worldwide rights excluding the Zaiming Territory (China, Hong Kong, Macau, and Taiwan), where Simcere Zaiming Pharmaceutical Co., Ltd. retains exclusive rights.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: Not applicable (no product sales revenue)
• Operating Margin: Not applicable (no product sales revenue)
• Net Margin: Not applicable (no product sales revenue)

Investment in Growth:

• R&D Expenditure: $44.9 million (increased 8% YoY)
• Capital Expenditures: $0 (2025) vs. $0.5 million (2024)
• Strategic Investments:
  • License Agreement with Simcere Zaiming Pharmaceutical Co., Ltd.: $18.5 million expensed in 2025, including a $12 million upfront payment, a $5 million payment due December 31, 2025, and a $1.5 million Phase 1 milestone payment.
  • Co-development with LigaChem Biosciences, Inc. for LNCB74, resulting in a $2.5 million reduction in NextCure, Inc.'s research and development costs in 2025 due to 50:50 cost sharing.

Business Segment Analysis

NextCure, Inc. operates in a single reportable segment: life sciences.

SIM0505

Financial Performance:

• Revenue: Not applicable (no product sales)
• Key Growth Drivers:
  • Novel ADC targeting CDH6 with a unique binding epitope designed for increased tumor binding.
  • Proprietary Topoisomerase 1 inhibitor (TOPOi) payload (CPT116) engineered for broad anti-tumor activity and fast systemic clearance to enlarge the therapeutic window.
  • Preclinical studies demonstrated robust anti-tumor activity across multiple solid tumor models and a promising safety profile.

Product Portfolio:

• SIM0505: An ADC candidate directed to cadherin-6 (CDH6), featuring a proprietary TOPO1 payload (CPT116) with a drug-to-antibody ratio (DAR) of 8. The linker is a Gly-Gly-Phe-Gly linker designed for tumor-specific cleavage.
• New product launches or major updates: First patient dosed in the U.S. Phase 1 clinical trial in October 2025. Phase 1 dose escalation data readout is expected in the second quarter of 2026.

Market Dynamics:

• Competitive positioning within segment: SIM0505 faces competition from other CDH6-targeted programs, including raludotatug deruxtecan (co-developed by Merck & Co. and Daiichi Sankyo), OnCusp Therapeutics' CUSP06, and Hansoh Pharma’s HS-20124. It also competes with alternative targeted modalities in ovarian cancer such as Folate Receptor Alpha (FRα) therapies (AbbVie’s Elahere, Genmab’s rinatabart sesutecan) and NaPi2b-targeting TUB-040.
• Key customer types and market trends: The clinical program places a strategic emphasis on gynecological cancers, particularly platinum-resistant ovarian cancer, while also evaluating other histologically defined CDH6-expressing tumor types including renal (clear cell and papillary renal cell carcinoma), lung (adenocarcinoma of non-small cell lung cancer), and endometrial/uterine serous cancers.

LNCB74

Financial Performance:

• Revenue: Not applicable (no product sales)
• Key Growth Drivers:
  • State-of-the-art B7-H4 targeted ADC designed for potential improved safety and efficacy.
  • B7-H4 is a clinically validated target expressed on multiple tumor types including breast, ovarian, and endometrial cancers.
  • Preclinical studies demonstrated potent tumor killing in disease models and a favorable safety profile.

Product Portfolio:

• LNCB74: An anti-B7-H4 ADC comprised of a NextCure, Inc. generated mAb intermediate with an Fc modification to protect immune cells, conjugated with a LigaChem Biosciences, Inc. developed beta-glucuronide cleavable linker technology (ConjuAll) and a Monomethyl auristatin E (MMAE) toxin payload (DAR of 4). The MMAE payload allows for bystander killing of neighboring tumor cells while minimizing toxicity in non-tumor cells.
• New product launches or major updates: First patient dosed in Phase 1 trial in January 2025. FDA cleared a protocol amendment in November 2025 to add higher dose escalation cohorts. A trial update, including proof of concept data, is planned for the second half of 2026, with expanded dosing and enrollment prioritizing patients with high B7-H4 expression in breast and gynecological cancers, and adding adenoid cystic carcinoma type 1 (ACC-1).

Market Dynamics:

• Competitive positioning within segment: LNCB74 will compete with a range of B7-H4 targeted programs currently in clinical trials from companies including AstraZeneca plc, BeiGene Ltd. (licensed from DualityBio), GSK plc (licensed from Hansoh Pharmaceutical Group Limited), and Day One Biopharmaceuticals, Inc. (acquired Mersana Therapeutics). Additional B7-H4 ADCs in preclinical development and other B7-H4 targeting therapeutics that are not ADCs also represent competition.
• Key customer types and market trends: Focus on multiple cancers known to have high B7-H4 expression, including breast, ovarian, endometrial cancers, and adenoid cystic carcinoma type 1 (ACC-1).

Other Clinical Programs (NC410, NC525)

Financial Performance:

• Revenue: Not applicable (no product sales)
• Key Growth Drivers: NextCure, Inc. is actively seeking partners to further develop these programs.
• NC410: A fusion protein of LAIR-2, designed to block immune suppression mediated by LAIR-1. Early preclinical correlative biomarker work suggests potential to overcome tumor resistance by remodeling the tumor’s extracellular matrix. NextCure, Inc. holds exclusive worldwide rights.
• NC525: A novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML) blast cells and leukemic stem cells (LSCs), while sparing hematopoietic stem and progenitor cells (HSPCs). Preclinical data indicate inhibition of AML growth and restriction of AML progression. NextCure, Inc. holds exclusive worldwide rights.

Preclinical Programs (NC181, NC605)

Financial Performance:

• Revenue: Not applicable (no product sales)
• Key Growth Drivers: NextCure, Inc. is pursuing a partner or third-party financing to advance these programs.
• NC181: A humanized antibody targeting ApoE4 for the treatment of Alzheimer’s disease (AD). Preclinical studies demonstrated amyloid clearance, prevention of amyloid deposition, plaque clearance, reduced neuroinflammation, reduced microhemorrhages, and improved cerebral vascular function. NextCure, Inc. holds exclusive worldwide rights.
• NC605: An antibody that targets Siglec-15. Preclinical data reported reduced bone loss and enhanced bone quality in mice with Osteogenesis Imperfecta (OI). Potential applications in chronic bone diseases such as osteoarthritis and non-union fractures. NextCure, Inc. holds exclusive worldwide rights.
• Both NC181 and NC605 have the potential to file an Investigational New Drug (IND) application within 12 to 18 months if financial support from partners or third parties is secured.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: None disclosed.
• Dividend Payments: NextCure, Inc. has never declared or paid cash dividends and does not anticipate doing so in the foreseeable future, intending to retain all available funds and future earnings for business development and expansion.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position:

• Cash and Equivalents: $25.982 million (as of December 31, 2025)
• Total Debt: Lease liabilities (current and long-term) total $5.153 million long-term and $1.005 million current portion as of December 31, 2025. No other material debt is disclosed.
• Net Cash Position: $41.8 million (Cash, cash equivalents and marketable securities) as of December 31, 2025.
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Lease liabilities mature through March 2030.

Cash Flow Generation:

• Operating Cash Flow: $(49.6) million (2025)
• Free Cash Flow: Not explicitly stated, but negative given operating cash flow and minimal capital expenditures.
• Cash Conversion Metrics: Not explicitly detailed, but the company has incurred net losses and negative operating cash flows since inception.

Operational Excellence

Production & Service Model: NextCure, Inc. previously operated a purpose-built, dedicated, state-of-the-art cGMP manufacturing facility with a production capacity of 2,000 liters. In March 2024, as part of a restructuring, the company paused its internal manufacturing operations, having produced ample clinical monoclonal antibody (mAb) supply, including the LNCB74 mAb intermediate, for near-term program needs. The facility is maintained for potential future cGMP manufacturing use. The company now relies on third-party contract manufacturing organizations (CMOs) for certain manufacturing elements, including Master Cell Bank manufacturing and fill-finish services.

Supply Chain Architecture: Key Suppliers & Partners:

• [CDMO for LNCB74]: WuXi XDC - The sole contract development and manufacturing organization (CDMO) currently used for conjugating the B7-H4 antibody and producing LNCB74 ADC drug product. WuXi XDC is affiliated with WuXi AppTec.
• [General Manufacturing Partners]: Third-party contract manufacturing organizations (CMOs) - Provide Master Cell Bank manufacturing and fill-finish services for product candidates.
• [Clinical Research Organizations]: Third-party CROs - Conduct GLP-compliant preclinical studies and cGCP-compliant clinical trials.
• [Research Institutions]: Medical institutions, clinical investigators, contract laboratories - Support preclinical and clinical development.

Facility Network:

• Manufacturing: Corporate headquarters in Beltsville, Maryland, includes approximately 20,600 square feet of laboratory and manufacturing space. Internal manufacturing operations are currently paused but the facility is maintained for potential future cGMP use.
• Research & Development: Corporate headquarters in Beltsville, Maryland, includes approximately 20,600 square feet of laboratory space.
• Distribution: Corporate headquarters in Beltsville, Maryland, includes approximately 20,200 square feet of warehouse space.

Operational Metrics:

• Workforce Reduction: Approximately 37% reduction in workforce in March 2024.
• Manufacturing Pause: Internal manufacturing operations paused in March 2024.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: NextCure, Inc. does not currently possess a sales or marketing infrastructure. If product candidates receive marketing approval, the company expects to build a focused sales and marketing organization in the United States.
• Channel Partners: The company may seek to establish additional collaborations and strategic partnerships for the development and potential commercialization of its product candidates.
• Digital Platforms: Not explicitly detailed for sales or distribution.

Customer Portfolio: Enterprise Customers:

• Strategic Partnerships:
  • Simcere Zaiming Pharmaceutical Co., Ltd.: License agreement for SIM0505 development and commercialization (ex-Zaiming Territory).
  • LigaChem Biosciences, Inc.: Co-development agreement for LNCB74 (50:50 cost/profit sharing).
• Customer Concentration: Not applicable as NextCure, Inc. has no commercial products or customers.

Geographic Revenue Distribution:

• NextCure, Inc. has not generated any revenue from product sales.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biotechnology and pharmaceutical industries, particularly the oncology subsector, are characterized by rapid technological evolution, intense competition, and strong defense of intellectual property. The market includes major pharmaceutical companies, specialty pharmaceutical companies, universities, governmental agencies, and research institutions. Many competitors possess significantly greater financial, manufacturing, marketing, product development, technical, and human resources. Mergers and acquisitions further concentrate resources among fewer competitors. Key Trends: Rapid technological change, focus on cancer immunotherapies, development of antibody-drug conjugates (ADCs), and immune checkpoint inhibitors.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• For SIM0505 (CDH6-targeted ADCs):
  • Merck & Co. and Daiichi Sankyo: Co-developing raludotatug deruxtecan (Phase 2/3 candidate).
  • OnCusp Therapeutics: Developing CUSP06 (early-stage).
  • Hansoh Pharma: Developing HS-20124 (early-stage).
  • Alternative Ovarian Cancer Therapies: AbbVie (Elahere, FRα), Genmab (rinatabart sesutecan, FRα), and TUB-040 (NaPi2b).
• For LNCB74 (B7-H4-targeted ADCs):
  • AstraZeneca plc
  • BeiGene Ltd. (licensed from DualityBio)
  • GSK plc (licensed from Hansoh Pharmaceutical Group Limited)
  • Day One Biopharmaceuticals, Inc. (acquired Mersana Therapeutics)
  • Other companies with preclinical B7-H4 ADCs and non-ADC therapeutics.

Emerging Competitive Threats: New entrants, disruptive technologies, and alternative solutions in immuno-oncology and targeted cancer therapies. The biopharmaceutical industry's rapid technological change means competitors' advances could render NextCure, Inc.'s product candidates obsolete or less competitive.

Competitive Response Strategy: NextCure, Inc.'s strategy focuses on differentiating SIM0505 and LNCB74 through their proprietary payloads, optimized safety profiles, and efficacy across specific tumor types. The company also seeks to partner other clinical and preclinical programs to leverage external resources and expertise.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Limited Operating History & Profitability: NextCure, Inc. has a limited operating history, no approved products, and a history of significant net losses ($55.8 million in 2025, $436.0 million accumulated deficit). It expects continued losses and may never achieve profitability.
• Unproven Discovery Approach: The proprietary FIND platform for target identification is novel and unproven in generating marketable products, posing a risk that product candidates derived from it may not achieve marketing approval.
• Market Acceptance: Even if approved, product candidates may fail to gain sufficient market acceptance by physicians, patients, and third-party payors due to established therapies, adverse events in clinical trials, or negative public perception of cancer immunotherapies.
• Limited Market Opportunities: Initial approvals may be limited to patients ineligible for or failed by established therapies, potentially resulting in small addressable patient populations and insufficient revenue without additional indications.
• Combination Therapy Risks: Developing product candidates in combination with other therapies exposes NextCure, Inc. to risks of synergistic activity failure, failure to achieve superior outcomes, or unforeseen toxicities. Dependency on third-party therapies also poses risks of revocation of approval, supply issues, or market displacement.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Manufacturing Experience & Capacity: NextCure, Inc. has limited manufacturing experience, particularly after pausing internal operations in March 2024. Failure to secure sufficient third-party manufacturing capacity, or to manufacture economically, at scale, or in compliance with cGMP, could delay clinical trials and commercialization.
• Supplier Dependency: Reliance on third-party suppliers for key materials (e.g., WuXi XDC for LNCB74 ADC drug product) creates risks related to pricing, availability, quality, delivery schedules, and potential disruptions from regulatory actions (e.g., BIOSECURE Act impacting WuXi AppTec affiliates).
• Capacity Constraints: Scaling up manufacturing for late-stage development and commercialization may require significant additional expenses and personnel, with no assurance of timely or economical success.

Financial & Regulatory Risks

Market & Financial Risks:

• Need for Additional Capital: NextCure, Inc. requires substantial additional financing to fund operations beyond the first half of 2027, raising substantial doubt about its ability to continue as a going concern. Failure to obtain capital could force delays, reductions, or termination of product development or commercialization efforts.
• Stock Price Volatility: The price of NextCure, Inc.'s common stock has been and is likely to remain volatile, influenced by clinical trial results, regulatory decisions, competitive developments, and financing activities.
• Dilution: Future equity offerings to raise capital will dilute existing stockholders' ownership interests.
• Net Operating Loss Limitations: The ability to use net operating loss carryforwards ($310.9 million federal, $314.0 million state as of December 31, 2025) to offset future taxable income may be limited by IRC Sections 382 and 383 due to ownership changes.

Regulatory & Compliance Risks:

• Lengthy & Unpredictable Regulatory Approval: The FDA and foreign regulatory approval processes are lengthy, expensive, and inherently unpredictable. Failure to obtain approval for product candidates would materially harm the business.
• Ongoing Regulatory Obligations: Even with approval, products are subject to extensive and ongoing regulatory requirements (e.g., cGMP, cGCP, adverse event reporting, advertising/promotion restrictions), which can result in significant additional expense, administrative and judicial enforcement, or withdrawal of approval if not complied with.
• Companion Diagnostics Regulation: If required, developing and obtaining regulatory approval for companion diagnostics (regulated as medical devices) could be time-consuming and costly, delaying product commercialization.
• Healthcare Regulation & Reimbursement: The ability to commercialize products depends on coverage and adequate reimbursement from third-party payors. Uncertainty in pricing policies, cost containment initiatives (e.g., ACA, IRA), and potential for lower reimbursement rates could limit market access and revenue.
• Anti-Kickback, Fraud & Abuse Laws: Relationships with healthcare providers and payors are subject to complex federal and state healthcare fraud and abuse laws, violations of which could lead to significant penalties, reputational harm, and operational restrictions.
• Environmental, Health & Safety: Operations involve hazardous materials, posing risks of contamination, injury, fines, or penalties if environmental, health, and safety laws are not complied with.
• Judicial Scrutiny of Agency Action: A U.S. Supreme Court ruling in June 2024 on the Administrative Procedure Act may increase challenges to agency interpretations of law, potentially leading to greater uncertainty, delays, and increased costs in regulatory processes.

Geopolitical & External Risks

Geographic Dependencies: Reliance on foreign CMOs (e.g., WuXi XDC) for manufacturing exposes NextCure, Inc. to geopolitical risks and trade law changes. Trade Relations: The BIOSECURE Act (signed into law December 18, 2025) could restrict U.S. pharmaceutical companies from collaborating with certain Chinese entities (e.g., WuXi AppTec affiliates), potentially impacting NextCure, Inc.'s manufacturing and development capabilities. Sanctions & Export Controls: Compliance with sanctions and export controls is required, and changes could limit business activities.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Antibody-Drug Conjugates (ADCs): Primary focus, leveraging two distinct payloads (Topoisomerase 1 inhibitor for SIM0505 and Tubulin Inhibitor for LNCB74) and unique antibody/linker technologies.
• Targeted Therapies: Advancing medicines that treat cancer patients who do not respond to or progress on current therapies.
• Biological Pathways & Biomarkers: Core strength in understanding these elements, cell interactions in the tumor microenvironment, and their role in biologic response.
• FIND Platform: Proprietary Functional, Integrated, NextCure Discovery platform for identifying novel targets.
• Immunotherapies: Developing therapies to block immune suppression (e.g., NC410, NC525). Innovation Pipeline:
• SIM0505: CDH6-targeted ADC in Phase 1 dose escalation (U.S. and China).
• LNCB74: B7-H4-targeted ADC in Phase 1 dose escalation/expansion.
• NC410 (LAIR-2 fusion protein) & NC525 (LAIR-1 antibody): Clinical oncology programs seeking partners.
• NC181 (ApoE4 antibody for AD) & NC605 (Siglec-15 antibody for OI): Preclinical non-oncology programs seeking partners/financing, with potential IND filings within 12-18 months if funded.

Intellectual Property Portfolio:

• Patent Strategy: Relies on a combination of patents, patent applications, and trade secrets. Files patent applications in the U.S. and internationally for product candidates, methods of use, and manufacturing processes.
• Patent Holdings: Over 40 U.S. and foreign granted patents or pending patent applications for LNCB74 (expected expiry 2039+) and SIM0505 (expected expiry 2044+).
• Licensing Programs: Exclusive, royalty-bearing, sublicensable worldwide license from Yale University for an intellectual property portfolio including patents related to NC318 (S15 methods of use) and the FIND platform (expected expiry 2036+).
• IP Litigation: NextCure, Inc. is subject to potential lawsuits to protect or enforce IP, or defend against infringement claims. A lawsuit filed in 2021 (claims added in 2022) against the Company and its Chief Executive Officer alleges breach of contractual and fiduciary duties and improper use of confidential information.

Technology Partnerships:

• Simcere Zaiming Pharmaceutical Co., Ltd.: License agreement for SIM0505 and non-exclusive license to use Zaiming’s ADC platform technology.
• LigaChem Biosciences, Inc.: Research Collaboration and Co-Development Agreement for ADCs, including LNCB74.
• Yale University: Exclusive license for certain intellectual property.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: NextCure, Inc. is highly dependent on its executive team and key personnel. The loss of services of any of them may adversely impact the achievement of objectives. Recruiting and retaining qualified employees, particularly scientific and technical personnel, is critical in a competitive labor market.

Board Composition: The Board of Directors, with the assistance of the Audit Committee, has oversight for significant risks, including cybersecurity. The Board receives annual updates on cybersecurity risks from the Audit Committee. The board is classified, and provisions in charter documents and Delaware law could delay or prevent an acquisition or change in management.

Human Capital Strategy

Workforce Composition:

• Total Employees: 40 full-time employees (as of December 31, 2025).
• Geographic Distribution: Not explicitly detailed, but operations are exclusively in the United States.
• Skill Mix: Success depends on attracting and retaining highly qualified management and technical personnel, particularly scientific and technical staff.

Talent Management: Acquisition & Retention:

• Hiring Strategy: Recruitment in a competitive labor market.
• Retention Metrics: Turnover rate is monitored.
• Employee Value Proposition: Competitive compensation and benefits, participation in equity programs.

Environmental & Social Impact

Environmental Commitments: Not explicitly detailed in the provided text. Supply Chain Sustainability: Not explicitly detailed in the provided text. Social Impact Initiatives: Not explicitly detailed in the provided text.

Business Cyclicality & Seasonality

Demand Patterns: Not explicitly detailed for product candidates as they are in development. The company's business is subject to risks common to early-stage biotechnology companies. Planning & Forecasting: Not explicitly detailed.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• FDA Regulation of Biologics: Product candidates are regulated as biological products under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act. The process involves extensive preclinical testing, IND applications, clinical trials (Phase 1, 2, 3), BLA submission and review, and post-approval requirements (e.g., cGMP, cGCP, adverse event reporting, advertising/promotion restrictions).
• Companion Diagnostics: In vitro companion diagnostics are generally regulated as high-risk, Class III medical devices by the FDA, requiring PMA approval, and should be approved contemporaneously with the therapeutic product.
• Laboratory Developed Tests (LDTs): Historically, the FDA generally did not enforce premarket review for LDTs. However, the FDA finalized a rule in May 2024 asserting that LDTs are medical devices subject to requirements, with phased enforcement over four years.
• Healthcare Fraud & Abuse Laws: Business arrangements with healthcare providers and payors are subject to federal and state anti-kickback statutes, false claims laws, HIPAA, and other regulations.
• Trade Laws: Subject to U.S. and foreign anti-corruption, anti-money laundering, export control, and sanctions laws (e.g., FCPA).
• Environmental, Health & Safety Laws: Compliance with laws governing laboratory procedures and handling/disposal of hazardous materials and wastes. International Compliance: Regulatory approval processes vary among jurisdictions and can involve different requirements and administrative review periods.

Trade & Export Controls:

• Export Restrictions: The BIOSECURE Act (signed into law December 18, 2025) could restrict U.S. pharmaceutical companies from collaborating with certain Chinese entities (e.g., WuXi AppTec affiliates), potentially impacting NextCure, Inc.'s manufacturing and development capabilities.
• Sanctions Compliance: Compliance with sanctions and export controls is required.

Legal Proceedings: NextCure, Inc. is not a party to any material litigation or legal proceedings, nor is management aware of any pending or threatened litigation likely to materially affect the business or financial results, except for a lawsuit filed in 2021 (claims added in 2022) against the Company and its Chief Executive Officer alleging breach of contractual and fiduciary duties and improper use of confidential information.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: 0% (due to a full valuation allowance against deferred tax assets).
• Geographic Tax Planning: NextCure, Inc. files income tax returns in the U.S. federal jurisdiction, Maryland, and Florida.
• Tax Reform Impact: The One Big Beautiful Bill Act (enacted July 4, 2025) does not currently have a significant impact due to NextCure, Inc.'s history of operating losses and full valuation allowances. The Inflation Reduction Act of 2022 and other healthcare reform measures could impact future drug pricing and reimbursement.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: NextCure, Inc. maintains trial liability insurance coverage consistent with industry standards. The company intends to expand its insurance coverage for products to include the sale of commercial products if marketing approval is obtained.
• Risk Transfer Mechanisms: Not explicitly detailed beyond insurance.